RAYMUND TAN: Open Payments
NPI 1780876227 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,077 in 120 payments from 15 companies in 2025. Trend: 2023 $1,378 · 2024 $2,698 · 2025 $2,077
Food & beverage: $2,073Education: $4
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $273 |
| E.R. Squibb & Sons, L.L.C. | 16 | $262 |
| Neurocrine BioSciences, Inc. | 9 | $260 |
| Supernus Pharmaceuticals, Inc. | 20 | $233 |
| Teva Pharmaceuticals USA, Inc. | 13 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $170 |
| Axsome Therapeutics, Inc. | 9 | $163 |
| Janssen Pharmaceuticals, Inc | 9 | $161 |
| Otsuka America Pharmaceutical, Inc. | 6 | $129 |
| Collegium Pharmaceutical, Inc. | 5 | $93 |
Products named: ARISTADA, COBENFY, INGREZZA, Qelbree, CAPLYTA, Auvelity, REXULTI, INVEGA SUSTENNA.
Industry payments across MO — which companies pay providers there.
